Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Monday 29 June 2026 (9)
  • Until platform closure (21)
Poster categories
  • Thematic Poster Session (34)
keywords
Session Reference
  • L-TPS01 (12)
  • L-TPS02 (14)
  • L-TPS03 (10)
  • L-TPS04 (13)
  • L-TPS05 (10)
  • L-TPS06 (8)
  • L-TPS07 (14)
  • L-TPS08 (9)
  • L-TPS09 (13)
  • L-TPS10 (14)
  • L-TPS11 (15)
  • L-TPS12 (11)
  • L-TPS13 (12)
  • L-TPS14 (14)
  • L-TPS15 (12)
  • L-TPS16 (9)
  • L-TPS17 (13)
  • L-TPS18 (13)
  • L-TPS19 (9)
  • L-TPS20 (14)
  • L-TPS21 (8)
  • L-TPS22 (10)
  • L-TPS23 (14)
  • L-TPS24 (14)
  • L-TPS25 (5)
  • TPS01 (14)
  • TPS02 (12)
  • TPS03 (10)
  • TPS04 (12)
  • TPS05 (13)
  • TPS06 (14)
  • TPS07 (9)
  • TPS08 (15)
  • TPS09 (14)
  • TPS10 (11)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (9)
  • TPS16 (12)
  • TPS17 (12)
  • TPS18 (11)
  • TPS19 (11)
  • TPS20 (13)
  • TPS21 (14)
  • TPS22 (11)
  • TPS23 (11)
  • TPS24 (12)
  • TPS25 (8)
  • TPS26 (16)
  • TPS27 (13)
  • TPS28 (5)
  • TPS29 (6)
  • TPS30 (12)
  • TPS31 (10)
  • TPS32 (12)
  • TPS33 (14)
  • TPS34 (15)
  • x TPS35 (11)
  • TPS36 (11)
  • TPS37 (12)
  • TPS38 (12)
  • TPS39 (13)
  • TPS40 (10)
  • x TPS41 (14)
  • TPS42 (15)
  • TPS43 (15)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (11)
  • TPS47 (14)
  • TPS48 (11)
  • TPS49 (12)
  • TPS50 (9)
  • TPS51 (8)
  • TPS52 (14)
  • TPS53 (12)
  • TPS54 (11)
  • TPS55 (13)
  • TPS56 (13)
  • TPS57 (5)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (12)
  • TPS61 (12)
  • TPS62 (13)
  • TPS63 (12)
  • TPS64 (15)
  • TPS65 (14)
  • TPS66 (13)
  • TPS67 (13)
  • TPS68 (11)
  • TPS69 (15)
  • TPS70 (13)
  • x TPS71 (9)
  • TPS72 (13)
  • TPS73 (12)
  • TPS74 (10)
  • TPS75 (13)
  • TPS76 (10)
  • TPS77 (7)
  • TPS78 (14)
  • TPS79 (13)
  • TPS80 (11)
  • TPS81 (6)
  • TPS82 (12)
  • TPS83 (6)
  • TPS84 (11)
  • TPS85 (11)
  • TPS86 (13)
  • TPS87 (10)
  • TPS88 (9)
  • TPS89 (7)
  • TPS90 (5)
  • TPS91 (5)
34 results
Thumbnail

D2.114 - Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure

Thumbnail

D2.115 - Occupational asthma and rhinitis to isocyanates in industrial settings

Thumbnail

D2.105 - A Newly Identified Indoor Fungus, Fusarium hechiense, Modulates Allergic Airway Inflammation in a Murine Asthma Model

Thumbnail

D2.107 - Genotype–Phenotype Segregation in Chronic Rhinosinusitis with Nasal Polyp and associated comorbid Asthma: Multivariate Clustering of Interleukin-4, Interleukin-6, Interleukin-13, and TNF-α Variants with Type-2 Biomarkers and Clinical Traits

Thumbnail

D2.108 - Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents

Thumbnail

D2.109 - Single-Cell Sequencing Reveals the Immunological Mechanism of Astragaloside IV in the Treatment of Allergic Rhinitis Complicated with Asthma

Thumbnail

D2.110 - Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study

Thumbnail

D2.112 - The Impact of Inflammation on Protective Immune Responses in the Airways

Thumbnail

D2.113 - Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF25–75 Levels

Thumbnail

D2.120 - Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update

Thumbnail

D2.121 - Seroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment

Thumbnail

D2.216 - Effectiveness and safety of subcutaneous immunotherapy with Depigmented-Polymerized Cat Extract: real-world clinical evidence

Thumbnail

D2.217 - Structured Follow-Up Intervals Enhance Adherence to Sublingual Immunotherapy in Patients with Allergic Rhinitis: Real-World Evidence from a Stepwise Approach

Thumbnail

D2.218 - Effectiveness of the 300IR house dust mite sublingual tablet according to the patients’ sensitisation and allergy profile in the real-world, non-interventional VORAN study

Thumbnail

D2.219 - Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis

Thumbnail

D2.222 - A real-world observational study following the first year of SQ grass or SQ tree SLIT-tablet treatment to evaluate persistence and adherence in routine clinical practice among general practitioners in Norway

Thumbnail

D2.225 - Characterizing skin-resident antigen presenting cell responses to plant-based Fel d 1 Bioparticles

Thumbnail

D2.226 - Evaluation of the Immunogenicity and Stability of an Aluminum-Adsorbed Allergen Immunotherapy Using Specific IgG Titration in a Murine Model

Thumbnail

D2.228 - Effectiveness and Safety of Subcutaneous Immunotherapy for Patients Allergic to Either Cat Dander or Dermatophagoides/Cat Dander: Real World Data

Thumbnail

D2.214 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: 3-year interim results of a long-term NIS

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM